Tim Dyer, Neurosterix CEO

Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Small Swiss biotech Ad­dex Ther­a­peu­tics is trans­fer­ring its neu­ro­science as­sets and its al­losteric mod­u­la­tor plat­form to a new biotech that has picked up $63 mil­lion in a Se­ries A raise.

The 22-year-old pub­licly trad­ed Ad­dex will own about 20% of the new com­pa­ny called Neu­roster­ix, CEO Tim Dy­er said in an in­ter­view with End­points News ahead of the Wednes­day an­nounce­ment.

Dy­er will lead both com­pa­nies, and Neu­roster­ix will take Ad­dex’s fa­cil­i­ty and team of 19 em­ploy­ees with it, he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.